Quest Diagnostics Enters Material Definitive Agreement

Ticker: DGX · Form: 8-K · Filed: 2024-07-03T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, regulatory-filing

TL;DR

Quest Diagnostics signed a new material agreement on July 2nd.

AI Summary

On July 2, 2024, Quest Diagnostics Incorporated entered into a Material Definitive Agreement. The filing also includes information regarding Regulation FD Disclosure and Financial Statements and Exhibits. The company's principal executive offices are located at 500 Plaza Drive, Secaucus, NJ 07094.

Why It Matters

This filing indicates a significant new agreement for Quest Diagnostics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting a material definitive agreement without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by Quest Diagnostics?

The filing does not specify the exact nature of the Material Definitive Agreement, only that one was entered into on July 2, 2024.

What other information is included in this 8-K filing?

This 8-K filing also includes information regarding Regulation FD Disclosure and Financial Statements and Exhibits.

Where are Quest Diagnostics' principal executive offices located?

Quest Diagnostics' principal executive offices are located at 500 Plaza Drive, Secaucus, NJ 07094.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is July 2, 2024.

Under which section of the Securities Exchange Act is this report filed?

This is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000947871-24-000587.txt : 20240703 0000947871-24-000587.hdr.sgml : 20240703 20240703091806 ACCESSION NUMBER: 0000947871-24-000587 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240702 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 241098374 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 ss3544770_8k.htm CURRENT REPORT false 0001022079 0001022079 2024-07-02 2024-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549         FORM 8-K       CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of Earliest Event Reported) : July 2, 2024     Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)   Delaware   (State or other jurisdiction of incorporation)       001-12215   16-1387862 (Commission File Number)   (I.R.S. Employer Identification No.)       500 Plaza Drive     Secaucus , NJ   07094 (Address of principal executive offices)   (Zip Code)         ( 973 ) 520-2700   (Registrant's telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐                 Item 1.01. Entry into a Material Definitive Agreement   On July 2, 2024, Quest Diagnostics Incorporated (the “Company”) and 1000923563 Ontario Inc., a subsidiary of the Company (the “Buyer”), entered into an Equity Purchase Agreement (the “Agreement”) with Borealis Infrastructure Corporation, a corporation incorporated under the federal laws of Canada (“Borealis”), BPC Healt

View on Read The Filing